Mutations in NR5A1 Associated with Ovarian Insufficiency by Lourenco, Diana et al.
Supplementary Appendix
This appendix has been provided by the authors to give readers additional information about their work.
Supplement to: Lourenço D, Brauner R, Lin L, et al. Mutations in NR5A1 associated with ovarian insufficiency. 






The authors collected and analyzed the data, and made the decision to submit the results for 
publication. Dr. Bashamboo and Dr McElreavey designed the study and wrote the manuscript, 
which was reviewed by all the authors. Dr Achermann assisted with manuscript revisions. 
 
Patient and control samples 
All 46,XY DSD patients met the revised criteria of the Pediatric Endocrine Society 
(LWPES)/European Society for Paediatric Endocrinology (ESPE) Consensus Group1. 
Families included in the study had at least one affected member with 46,XY DSD and at least 
one other member with 46,XX Primary Ovarian Insufficiency (POI). The study itself was 
approved by the Institut Pasteur (RBM 2003/8). Patient ancestry was determined by self 
reporting, based on responses to a personal questionnaire, which asked questions pertaining to 
the birthplace, languages and self-reported ethnicity of the participants, their parents and 
grandparents. 
The control panel consisted of 130 unrelated 46,XY males with known fertility of French 
ethnic origin and with no history of testicular anomalies (determined by self reporting). A 
series of 56 unrelated 46,XY men of Indian origin (Gujarati), each the father of at least two 
children, were also included as well as 69 DNA samples from unrelated Roma individuals, 57 
Brazilians and 89 Senegalese. Additional control samples were obtained from the HGDP-
CEPH panel, comprising 1,064 DNA samples from 52 worldwide populations 
(http://www.cephb.fr/HGDP-CEPH-Panel/)2. These samples were collected from a number of 
different laboratories by the Human Genome Diversity Project (HGDP) and CEPH in order to 
provide unlimited supplies of DNA for studies of sequence diversity. All samples used for 
this resource were collected with proper informed consent. The bank represents 26 different 
worldwide populations including 24 Senegalese and 45 Brazilian individuals. The ethnic 
origin of the individuals was obtained by a combination of self assessment and questionaire. 
To date, the DNAs have been typed genome wide with more the 650,000 SNPs and 853 
microsatellites3-6. The data from the numerous molecular studies that have been performed on 
these samples to date confirmed the ethnic identity of each sample. CEPH panel samples that 
were analysed in this study were matched for ancestry with the patient sample.  
 
To investigate the degree of rare genetic variation in the NR5A1 gene, the entire open-reading 
frame of the NR5A1 gene was sequenced in DNA from a panel of 140 individuals of mixed 
ethnic origin with normal semen parameters (Caucasian n=66, North African n=30, West 
African n=33, Asian n=5, Other, n=6). Of these 140 individuals, 66 were known to be fertile.   
 
Mutational analysis of NR5A1 
The coding exons of the NR5A1 gene (exons 2 to 7) were amplified from DNA extracted 
using conventional techniques from peripheral blood lymphocytes of each individual. We 
designed 7 pairs of primers to amplify by PCR the NR5A1 exons. Exon 2, F2: 5’ - 
GGGCACAGAGAGGGGATTAC - 3’; R2: 5’ - CTGCGGGAGCTGAGAGTC- 3’. Exon 3, 
F3: 5’-ATTCGTACGACGAGGACCTG- 3’; R3: 5’ - CGAAGGCCAATGGTACTATCC- 
3’. Exon 4 amplicon 1. F4: 5’-GTGTTGAGCAGGGGAGAGAG- 3’; R4: 5'- 
AGAGAAGGGCTCTGGGTAGC- 3’. Exon 4 amplicon 2 F4a: 5'-
TCTGAGTACCCGGAGCCTTA-3'; R4a 5'-AAGGATGGCCCTATCCAAAG-3'. Exon 5, F5 
5'- ATCTGGGTAGATGGGCACAG -3'; R5 5'- GTGGGGAAAGGGCTGATAAT-3'. Exon 
6, F6 5'- TCTGACCTGCACCTCCAATC-3'; R6 5'- CTCTGGCTGTCTCCACCTCT-3'. 
Exon 7, F7 5'- ATGCCCATGTCTTTGATGGT-3'; R7 5'-GGTGGGCATCAGAAAATGAA-
3'.  
 
The PCR amplification conditions were, F2/R2, F4a/R4a and F5/R5 - 95°C for 5 min 
followed by 35 cycles of 95°C 30s, 60°C 30s, 72°C 30s. F3/R3, F4/R4 F6/R6 and F7/R7 - 
95°C for 5’ followed by 35 cycles of 95°C 30s, 64°C 30s, 72°C 30s. A final elongation step 
of 72°C for 5’ was added in each case. 5 µl of each PCR fragments were then electrophorezed 
in a 2% agarose gel stained in ethidium bromide (1µg/mL) to verify the expected length of the 
amplified fragments. DNA sequence analysis was performed using at least 200 ng of purified 
DNA, 20 ng of primer and fluorescently labelled Taq DyeDeoxy terminator reaction mix 
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. 
DNA sequence was determined using an ABI 3700 automated DNA sequencer.  
 
Confirmation of N5RA1 mutations  
The frameshift mutations in families 1 and 4 were confirmed by resequencing independent 
PCR products. The missense mutation in family 2 creates a MScI restriction site in the 
amplification product of primers F5 and R5. To confirm this mutation, the DNA from the 
affected and 782 control individuals was amplified independently using primers F5 and R5.  
The resultant amplicons were digested with MScI restriction endonuclease (New England 
Biolabs) according to the manufacturer’s instructions. The digested fragments were then 
electrophoresed in a 3% agarose gel stained in ethidium bromide (1µg/mL) to verify the 
digestion. The missense mutation in family 3 removes an NlaIII restriction site in the F2/R2 
amplicon. To confirm this mutation, the DNA from the affected and 350 control individuals 
was amplified independently using primers F2 and R2. The resultant amplicons were digested 
with NlaIII restriction endonuclease (New England Biolabs) according to the manufacturer’s 
instructions. The digested fragments were then electrophorezed in a 3% agarose gel stained in 
ethidium bromide (1µg/mL) to verify the digestion. Two mutations were detected in the 
F4/R4 amplicon in DNA from sporadic case 2. The c.368G>C mutation creates an HaeII site 
whilst the c.386C>T mutation abolishes a BanI restriction site. To determine if these 
mutations were bi- or monoallelic a double digestion was performed according to the 
manufacturer’s instructions (New England Biolabs). The digested fragments were then 
electrophoresed in a 3% agarose gel stained in ethidium bromide (1µg/mL). 
 
The 9 bp deletion in the isolated case of non-syndromic ovarian insufficiency was confirmed 
by PCR amplification of the DNA from the affected and 400 control individuals, with a pair 
of primers, delF 5'-GCTGCCGTACGGCTACCCAGA-3' and delR 5'-
GGCTTTTGGTGGGCTCCTGCA-3', spanning the 9 bp deletion, The PCR amplification 
conditions were - 95°C for 5 min followed by 35 cycles of 95°C 30s, 64°C 30s, 72°C 30s.  A 
final elongation step of 72°C for 5’ was added in each case. 5 µl of each PCR fragments were 




NR5A1 expression vectors containing the p.Gly123Ala, p.Pro129Leu, c.666delC, 
p.Leu231_Leu233del and p.Asp293Asn variants were generated by site-directed mutagenesis 
(QuikChange, Stratagene) using wild-type (WT) human NR5A1 cDNA in a pCMX expression 
vector as a template. The entire coding sequence of all mutant plasmids was confirmed by 
direct sequencing prior to functional studies.  
 
Homology alignment and modeling of the 3-D structure of NR5A1 ligand banding 
domain (LBD) 
All sequences were obtained from the Ensembl database (http://www.ensembl.org) and 
aligned using the web based multiple sequence alignment software Clustal-W 
(www.ebi.ac.uk/clustalw/). The 3-D models of LBD of both the wild type and 
p.Leu231_Leu233 deleted NR5A1 were created using the web based interface 3D-JIGSAW 
(http://www.bmm.icnet.uk/~3djigsaw/). Images of the modeled proteins (schematic) were 
viewed and manipulated using WebLab ViewerLite software (Molecular Simulations, Inc.). 
 
Functional studies of NR5A1 activity 
Transient gene expression assays to assess NR5A1 function were performed in 96-well plates 
(TPP) using either tsa201 human embryonic kidney cells or Chinese hamster ovary (CHO) 
cells, lipofectamine 2000 (Invitrogen), and a Dual-Luciferase reporter assay system 
(Promega) with pRLSV40 Renilla luciferase (Promega) expression as a marker of transfection 
efficiency. pCMXWT or mutant NR5A1 expression vectors (2ng/well) were co-transfected 
into tsa201 cells with reporters containing NR5A1 (SF1) responsive minimal promoters 
((murine Cyp11a1, rat Cyp19a1) (100ng/well)) and in CHO cells with rat Cyp19a1 SF1 
responsive minimal promoter (100ng/well) 7,8.  Cells were lysed 24 hours later and luciferase 
assays  were performed (Dual Luciferase Reporter Assay system, Promega) using a FLUOstar 
Optima fluorescence microplate reader (BMG Labtech). All data were standardized for 
Renilla activity. Results are shown as the mean±SEM of three independent experiments, each 





 Family Individual Age 
(yrs) 
Karyotype Genotype Hormone levels 






2 III.4 45 46,XY G/A 8.35 5.92 3.37 
2 III.7 41 46,XY G/G 4.62 5.14 4.57 
2 III.9 35 46,XX G/A 2.67 4.52 na 
2   III.10 34 46,XY G/A 5.13 4.01 3.37 
2   III.12 29 46,XX G/A 10.17 3.84 na 
3      II.3 10 46,XX G/G 4.1 0.6 <0.05 
 
Table 1: Additional clinical and genotyping information of unaffected family members of 
pedigree 2 and pedigree 3.   
 
 
Supplementary Figure 1. Assay of NR5A1 transcriptional activity in CHO cells. The 
transcriptional activity of wild-type NR5A1 and variants associated with ovarian insufficiency 
was studied using the Cyp19a1 promoter in CHO cells. NR5A1 activity is shown as fold 
increase above baseline. Data represent the mean±SEM of three independent experiments, 
each performed in triplicate. 
 
           p.Met1Ile 
            1 ATGGACTATTCGTACGACGAGGACCTGGACGAGCTGTGCCCCGTGTGCGGGGA 
            1 -M--D--Y--S--Y--D--E--D--L--D--E--L--C--P--V--C--G--D 
  
    54 CAAGGTGTCCGGCTACCACTACGGACTGCTCACGTGTGAGAGCTGCAAGGGCTTCTTCAA 
    18 --K--V--S--G--Y--H--Y--G--L--L--T--C--E--S--C--K--G--F--F--K 
 
   114 GCGCACGGTGCAGAACAACAAGCACTACACGTGCACCGAGAGCCAGAGCTGCAAGATCGA 
    38 --R--T--V--Q--N--N--K--H--Y--T--C--T--E--S--Q--S--C--K--I--D 
 
   174 CAAGACGCAGCGCAAGCGCTGTCCCTTCTGCCGCTTCCAGAAATGCCTGACGGTGGGGAT 
    58 --K--T--Q--R--K--R--C--P--F--C--R--F--Q--K--C--L--T--V--G--M 
 
   234 GCGCCTGGAAGCCGTGCGCGCTGACCGTATGAGGGGTGGCCGGAACAAGTTTGGGCCGAT 
    78 --R--L--E--A--V--R--A--D--R--M--R--G--G--R--N--K--F--G--P--M 
 
   294 GTACAAGCGGGACCGGGCCCTGAAACAGCAGAAGAAGGCACAGATTCGGGCCAATGGCTT 
    98 --Y--K--R--D--R--A--L--K--Q--Q--K--K--A--Q--I--R--A--N--G--F 
 
               p.Gly123Ala     p.Pro129Leu c.390delG 
   354 CAAGCTGGAGACAGGGCCCCCGATGGGGGTGCCCCCGCCGCCCCCTCCCGCACCGGACTA 
   118 --K--L--E--T--G--P--P--M--G--V--P--P--P--P--P--P--A--P--D--Y 
                                            -R--P--L--P--H--R--T--T 
 
   414 CGTGCTGCCTCCCAGCCTGCATGGGCCTGAGCCCAAGGGCCTGGCCGCCGGTCCACCTGC 
   138 --V--L--P--P--S--L--H--G--P--E--P--K--G--L--A--A--G--P--P--A 
       --C--C--L--P--A--C--M--G--L--S--P--R--A--W--P--P--V--H--L--L 
 
   474 TGGGCCACTGGGCGACTTTGGGGCCCCAGCACTGCCCATGGCCGTGCCCGGTGCCCACGG 
   158 --G--P--L--G--D--F--G--A--P--A--L--P--M--A--V--P--G--A--H--G 
       --G--H--W--A--T--L--G--P--Q--H--C--P--W--P--C--P--V--P--T--G 
 
   534 GCCACTGGCTGGCTACCTCTACCCTGCCTTTCCTGGCCGTGCCATCAAGTCTGAGTACCC 
   178 --P--L--A--G--Y--L--Y--P--A--F--P--G--R--A--I--K--S--E--Y--P 
       --H--W--L--A--T--S--T--L--P--F--L--A--V--P--S--S--L--S--T--R 
 
   594 GGAGCCTTATGCCAGCCCCCCACAGCCTGGGCTGCCGTACGGCTACCCAGAGCCCTTCTC 
   198 --E--P--Y--A--S--P--P--Q--P--G--L--P--Y--G--Y--P--E--P--F--S 
       --S--L--M--P--A--P--H--S--L--G--C--R--T--A--T--Q--S--P--S--L 
   
              c.666delC                p.Leu231_Leu233del 
   654 TGGAGGGCCCAACGTGCCTGAGCTCATCCTGCAGCTGCTGCAGCTGGAGCCGGATGAGGA 
   218 --G--G--P--N--V--P--E--L--I--L--Q--L--L--Q--L--E--P--D--E--D 
       --F--G--P--T--C--L--S--S--S--C--S--C--C--S--W--S--R--M--R--T 
                  K--C--L--S--S--S--C--S--C--C--S--W--S--R--M--R--T 
 
   714 CCAGGTGCGGGCCCGCATCTTGGGCTGCCTGCAGGAGCCCACCAAAAGCCGCCCCGACCA 
   238 --Q--V--R--A--R--I--L--G--C--L--Q--E--P--T--K--S--R--P--D--Q 
       --R--C--G--P--A--S--W--A--A--C--R--S--P--P--K--A--A--P--T--S 
       --R--C--G--P--A--S--W--A--A--C--R--S--P--P--K--A--A--P--T--S 
 
   774 GCCGGCGGCCTTCGGCCTCCTGTGCAGAATGGCCGACCAGACCTTCATCTCCATCGTGGA 
   258 --P--A--A--F--G--L--L--C--R--M--A--D--Q--T--F--I--S--I--V--D 
       --R--R--P--S--A--S--C--A--E--W--P--T--R--P--S--S--P--S--W--T 
       --R--R--P--S--A--S--C--A--E--W--P--T--R--P--S--S--P--S--W--T 
 
                                             p.Asp293Asn 
   834 CTGGGCACGCAGGTGCATGGTCTTCAAGGAGCTGGAGGTGGCCGACCAGATGACGCTGCT 
   278 --W--A--R--R--C--M--V--F--K--E--L--E--V--A--D--Q--M--T--L--L 
       --G--H--A--G--A--W--S--S--R--S--W--R--W--P--T--R--* 
       --G--H--A--G--A--W--S--S--R--S--W--R--W--P--T--R--* 
 
   894 GCAGAACTGCTGGAGCGAGCTGCTGGTGTTCGACCACATCTACCGCCAGGTCCAGCACGG 
   298 --Q--N--C--W--S--E--L--L--V--F--D--H--I--Y--R--Q--V--Q--H--G 
 
   954 CAAGGAGGGCAGCATCCTGCTGGTCACCGGGCAGGAGGTGGAGCTGACCACAGTGGCCAC 
   318 --K--E--G--S--I--L--L--V--T--G--Q--E--V--E--L--T--T--V--A--T 
 
  1014 CCAGGCGGGCTCGCTGCTGCACAGCCTGGTGTTGCGGGCGCAGGAGCTGGTGCTGCAGCT 
   338 --Q--A--G--S--L--L--H--S--L--V--L--R--A--Q--E--L--V--L--Q--L 
 
  1074 GCTTGCGCTGCAGCTGGACCGGCAGGAGTTTGTCTGCCTCAAGTTCATCATCCTCTTCAG 
   358 --L--A--L--Q--L--D--R--Q--E--F--V--C--L--K--F--I--I--L--F--S 
 
  1134 CCTGGATTTGAAGTTCCTGAATAACCACATCCTGGTGAAAGACGCTCAGGAGAAGGCCAA 
   378 --L--D--L--K--F--L--N--N--H--I--L--V--K--D--A--Q--E--K--A--N 
 
  1194 CGCCGCCCTGCTTGACTACACCCTGTGCCACTACCCGCACTGCGGGGACAAATTCCAGCA 
   398 --A--A--L--L--D--Y--T--L--C--H--Y--P--H--C--G--D--K--F--Q--Q 
 
  1254 GCTGCTGCTGTGCCTGGTGGAGGTGCGGGCCCTGAGCATGCAGGCCAAGGAGTACCTGTA 
   418 --L--L--L--C--L--V--E--V--R--A--L--S--M--Q--A--K--E--Y--L--Y 
 
  1314 CCACAAGCACCTGGGCAACGAGATGCCCCGCAACAACCTGCTCATCGAAATGCTGCAAGC 
   438 --H--K--H--L--G--N--E--M--P--R--N--N--L--L--I--E--M--L--Q--A 
 
  1374 CAAGCAGACTTGAGCCTGGGCCGGGGGCGGGGCCGGGACTGGGGGCGGGACTGGGGGCGG 
   458 --K--Q--T--* 
 
Supplementary Figure 2. The NR5A1 transcript. The positions of the mutations identified 
in this study are highlighted. The amino acid changes are indicated including the two 
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